Vor Biopharma Announces Board and Officer Changes
Ticker: VOR · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.34, $1.36, $44.96, $1.90 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, officer-appointment
TL;DR
Vor Bio's board and execs are shuffling; new faces in, old faces out.
AI Summary
Vor Biopharma Inc. announced on February 3, 2025, changes in its board and officer appointments. Specifically, the company reported the departure of certain officers and directors, along with the election of new directors and the appointment of new officers. The filing also covers compensatory arrangements for certain officers.
Why It Matters
Changes in leadership and board composition can signal shifts in company strategy, operational focus, or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, potentially impacting the company's trajectory.
Key Numbers
- 001-39979 — SEC File Number (Identifies Vor Biopharma Inc. in SEC filings.)
- 02140 — ZIP Code (Part of Vor Biopharma Inc.'s principal executive office address.)
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- February 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39979 (company_id) — SEC File Number
- 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140 (address) — Principal Executive Offices
- (617) 655-6580 (phone_number) — Registrant's telephone number
FAQ
What specific roles have been affected by the departure of officers and directors?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify the exact roles in this section.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 3, 2025.
What is Vor Biopharma Inc.'s state of incorporation?
Vor Biopharma Inc. is incorporated in Delaware.
What is the primary business of Vor Biopharma Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Does the filing detail the compensatory arrangements for the newly appointed officers?
The filing states that 'Compensatory Arrangements of Certain Officers' is an item covered, but the specific details of these arrangements are not provided in the excerpt.
Filing Stats: 961 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2025-02-06 16:01:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $1.34 — the " Inducement Plan ") was reduced to $1.34 per share (the " Reduced Exercise Price
- $1.36 — iously had exercise prices ranging from $1.36 to $44.96 per share. The Repriced Opt
- $44.96 — d exercise prices ranging from $1.36 to $44.96 per share. The Repriced Options inclu
- $1.90 — ecutive Officer 2,126,440 $ 4.301 $1.90 to $18.00 Tirtha Chakraborty Chief S
- $18.00 — fficer 2,126,440 $ 4.301 $1.90 to $18.00 Tirtha Chakraborty Chief Scientific
- $8.63 — Officer 625,189 $ 4.931 $1.36 to $8.63 Eyal Attar Chief Medical Officer 5
- $2.41 — f Medical Officer 598,000 $ 3.810 $2.41 to $5.55 The Board approved the Optio
- $5.55 — Officer 598,000 $ 3.810 $2.41 to $5.55 The Board approved the Option Reprici
Filing Documents
- d921842d8k.htm (8-K) — 31KB
- 0001193125-25-021763.txt ( ) — 154KB
- vor-20250203.xsd (EX-101.SCH) — 3KB
- vor-20250203_lab.xml (EX-101.LAB) — 18KB
- vor-20250203_pre.xml (EX-101.PRE) — 11KB
- d921842d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: February 6, 2025 By: /s/ Robert Ang Robert Ang Chief Executive Officer